Stockreport

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 [Yahoo! Finance]

Celldex Therapeutics, Inc.  (CLDX) 
Last celldex therapeutics, inc. earnings: 11/12 08:01 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celldex.com
PDF Abstracts will be available on the EADV Congress website at the start of the meeting. Presentation details are as follows: Abstract Title: Barzolvolimab shows profoun [Read more]